Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093.
VA San Diego Health Care System, La Jolla, California, USA.
J Clin Psychiatry. 2018 Oct 23;79(6):17m12038. doi: 10.4088/JCP.17m12038.
To evaluate the relationships between benzodiazepine use and (1) health care utilization and (2) suicide risk in veterans diagnosed with posttraumatic stress disorder (PTSD).
This propensity-matched retrospective cohort study included veterans diagnosed with 1 ICD-9 code for PTSD who were active users of the Veterans Affairs health care system between January 1, 2001, and December 31, 2014. Exposure included at least 1 thirty-day prescription of a benzodiazepine within 1 year following PTSD diagnosis among patients with no recent history of benzodiazepine use. The primary outcomes were health care utilization and suicidal behavior.
A total of 242,493 of 1,134,201 eligible veterans were included in the propensity-matched cohort, 80,831 (7.13%) of whom were prescribed benzodiazepines. Veterans with PTSD who received benzodiazepines had significantly more hospitalizations (incident rate ratio [IRR] = 1.27; 95% CI, 1.10-1.47) and emergency department (IRR = 1.16; 95% CI, 1.13-1.20), general outpatient (IRR = 1.19; 95% CI, 1.16-1.21), outpatient mental health (IRR = 1.49; 95% CI, 1.41-1.57), and total mental health (IRR = 1.37; 95% CI, 1.34-1.40) visits. Benzodiazepine users had a significantly greater risk of death due to suicide (hazard ratio [HR] = 2.74; 95% CI, 2.40-3.13) and were significantly more likely to have medically documented suicide attempts (HR = 1.85; 95% CI, 1.65-2.08) and suicidal ideation (HR = 1.57; 95% CI, 1.48-1.67).
Benzodiazepine users had higher rates of health care utilization and were more likely to attempt and complete suicide than patients without benzodiazepine exposure. This study strengthens the empirical evidence against the use of benzodiazepines in veterans with PTSD. Prescribers should weigh the benefits and risks-especially the almost 3-fold increase in suicide risk-when prescribing benzodiazepines in these patients.
评估苯二氮䓬类药物的使用与(1)退伍军人创伤后应激障碍(PTSD)患者的医疗保健利用以及(2)自杀风险之间的关系。
本倾向匹配回顾性队列研究纳入了 2001 年 1 月 1 日至 2014 年 12 月 31 日期间,在退伍军人事务部医疗保健系统中活跃使用的至少有 1 个 PTSD ICD-9 诊断代码的退伍军人。暴露包括在 PTSD 诊断后 1 年内至少有 1 次 30 天的苯二氮䓬类药物处方,且患者近期无苯二氮䓬类药物使用史。主要结局为医疗保健的利用和自杀行为。
在符合条件的 1134201 名退伍军人中,共有 242493 名接受了倾向匹配队列分析,其中 80831 名(7.13%)被开了苯二氮䓬类药物。使用苯二氮䓬类药物的 PTSD 退伍军人住院治疗(发病率比[IRR] = 1.27;95%置信区间,1.10-1.47)和急诊就诊(IRR = 1.16;95%置信区间,1.13-1.20)、普通门诊(IRR = 1.19;95%置信区间,1.16-1.21)、门诊心理健康(IRR = 1.49;95%置信区间,1.41-1.57)和总心理健康(IRR = 1.37;95%置信区间,1.34-1.40)的次数显著增加。苯二氮䓬类药物使用者的自杀死亡风险显著增加(风险比[HR] = 2.74;95%置信区间,2.40-3.13),并且有记录表明他们更有可能尝试和完成自杀(HR = 1.85;95%置信区间,1.65-2.08)以及自杀意念(HR = 1.57;95%置信区间,1.48-1.67)。
与未使用苯二氮䓬类药物的患者相比,使用苯二氮䓬类药物的退伍军人的医疗保健利用率更高,自杀的可能性也更大。本研究加强了苯二氮䓬类药物在 PTSD 退伍军人中使用的实证证据。在这些患者中开具苯二氮䓬类药物时,医生应权衡利弊,特别是考虑到自杀风险增加近 3 倍的情况。